<code id='36EF9156A8'></code><style id='36EF9156A8'></style>
    • <acronym id='36EF9156A8'></acronym>
      <center id='36EF9156A8'><center id='36EF9156A8'><tfoot id='36EF9156A8'></tfoot></center><abbr id='36EF9156A8'><dir id='36EF9156A8'><tfoot id='36EF9156A8'></tfoot><noframes id='36EF9156A8'>

    • <optgroup id='36EF9156A8'><strike id='36EF9156A8'><sup id='36EF9156A8'></sup></strike><code id='36EF9156A8'></code></optgroup>
        1. <b id='36EF9156A8'><label id='36EF9156A8'><select id='36EF9156A8'><dt id='36EF9156A8'><span id='36EF9156A8'></span></dt></select></label></b><u id='36EF9156A8'></u>
          <i id='36EF9156A8'><strike id='36EF9156A8'><tt id='36EF9156A8'><pre id='36EF9156A8'></pre></tt></strike></i>

          Home / hotspot / explore

          explore


          explore

          author:leisure time    Page View:1963
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In